| Biomarker ID | 240 |
| PMID | 18190830 |
| Year | 2007 |
| Biomarker | YKL- 40 |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa (PPC: 188.01 Vs BPH: 73.54 ± 9.25) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Interleukin-1 regulation of extracellular matrix,Interleukin-4 regulation of apoptosis,Oncostatin M,TGF-beta regulation of extracellular matrix |
| Experiment | Benign Prostatic Hyperplasia vs Primary Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Serum samples from 93 patients with primary prostate cancer, 61 with prostatic hyperplasia, and 56 controls were compared. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CHI3L1 |